U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06921213) titled 'Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis' on March 25.
Brief Summary: CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.
Study Start Date: Oct. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Syphilis, Congenital
Intervention:
DRUG: Linezolid (LZD)
Ten day course. Oral Linezolid dosed at 10mg/kg twice a day.
DRUG: Amoxicillin
Ten day course. Oral Linezolid dosed at 50mg/kg twice a day.
DRUG: Benzathine Penicillin G
Single IM dose 50,000iu/kg
Recrui...